BridgeBio is a biotechnology company dedicated to designing transformative medicines for patients with genetic diseases and cancers driven by clear genetic factors. Their mission is to discover, create, test, and deliver innovative treatments to address unmet medical needs. As a Contract Manufacturing Organisation (CMO) and Contract Development and Manufacturing Organisation (CDMO), BridgeBio offers a range of services tailored to support the pharmaceutical industry in developing effective therapies.

Services include:
- Drug development
- Scale-up manufacturing
- Quality control and assurance
- Regulatory support
- Clinical trial material production
- Commercial manufacturing

BridgeBio stands out in the pharmaceutical industry with its commitment to innovation and quality, ensuring the delivery of effective treatments for challenging conditions. For more information, visit bridgebio.com.